Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance of Response with Risperidone LAI in Schizophrenia
NCT01888107Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2005
- Primary completion
- Apr 2007
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of risperidone in schizophrenia and schizoaffective disorder, sponsored by Janssen Pharmaceutical. Primary endpoint: Positive and Negative Syndrome Scale at 52 weeks. Started Jan 2005; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT01888107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01888107.